Relmada Therapeutics
RLMD
83 hedge funds and large institutions have $56.4M invested in Relmada Therapeutics in 2023 Q4 according to their latest regulatory filings, with 7 funds opening new positions, 25 increasing their positions, 20 reducing their positions, and 16 closing their positions.
25% more repeat investments, than reductions
Existing positions increased: 25 | Existing positions reduced: 20
4.55% less ownership
Funds ownership: 49.8% → 45.25% (-4.6%)
5% less funds holding
Funds holding: 87 → 83 (-4)
42% less capital inflows, than outflows
Capital inflows: $6.6M | Capital outflows: $11.3M
56% less first-time investments, than exits
New positions opened: 7 | Existing positions closed: 16
79% less call options, than puts
Call options by funds: $296K | Put options by funds: $1.41M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OM
Opaleye Management
Boston,
Massachusetts
|
+$2.51M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
+$740K |
| 3 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$651K |
| 4 |
Two Sigma Advisers
New York
|
+$485K |
| 5 |
Marshall Wace
London,
United Kingdom
|
+$455K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RTW Investments
New York
|
-$6.4M |
| 2 |
Deep Track Capital
Greenwich,
Connecticut
|
-$2.35M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$478K |
| 4 |
Schonfeld Strategic Advisors
New York
|
-$328K |
| 5 |
Voloridge Investment Management
Jupiter,
Florida
|
-$274K |
RLMD Hedge Fund Activity: Q4 2023 in Review
83 of the 6,876 institutional investors tracked by Wall St. Rank reported a position in Relmada Therapeutics (RLMD) for Q4 2023, worth a combined $56.4M — up 25% from $45M a quarter earlier.
Sellers outnumbered buyers: 16 funds closed out of RLMD and 7 opened new positions — a net loss of 9 holders — while 20 trimmed existing stakes and 25 added.
The largest buyer was Opaleye Management, adding an estimated $2.51M. The largest seller was RTW Investments, exiting entirely with an estimated $6.4M sold.
- 83 institutional investors held Relmada Therapeutics (RLMD) as of Q4 2023, down from 87 in Q3 2023.
- Funds reported $56.4M of Relmada Therapeutics stock for Q4 2023, up 25% quarter-over-quarter.
- 7 funds opened new Relmada Therapeutics positions in Q4 2023 and 16 closed out, a net change of -9 holders.
- The largest Relmada Therapeutics buyer in Q4 2023 was Opaleye Management, an estimated $2.51M added.
- The largest Relmada Therapeutics seller in Q4 2023 was RTW Investments, an estimated $6.4M sold.
Based on aggregated 13F filings for Q4 2023.